NCT05966493Phase 2Recruiting

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED

Study sponsor: Glaukos Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-12Estimated
Enrollment · participants84Estimated
Source updated2025-07-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview